See more : Venture Corporation Limited (VEMLF) Income Statement Analysis – Financial Results
Complete financial analysis of 89bio, Inc. (ETNB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 89bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The Vita Coco Company, Inc. (COCO) Income Statement Analysis – Financial Results
- Exxe Group Inc. (AXXA) Income Statement Analysis – Financial Results
- Byline Bancorp, Inc. (BY) Income Statement Analysis – Financial Results
- Hisense Visual Technology Co., Ltd. (600060.SS) Income Statement Analysis – Financial Results
- KH Neochem Co., Ltd. (4189.T) Income Statement Analysis – Financial Results
89bio, Inc. (ETNB)
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 273.00K | 240.00K | 79.00K | 60.00K | 17.00K | 6.00K |
| Gross Profit | -273.00K | -240.00K | -79.00K | -60.00K | -17.00K | -6.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 122.23M | 80.80M | 70.33M | 36.20M | 21.35M | 13.68M |
| General & Administrative | 28.97M | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.97M | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Other Expenses | 0.00 | 242.00K | -526.00K | -203.00K | -30.56M | -986.00K |
| Operating Expenses | 151.20M | 102.25M | 89.74M | 49.36M | 26.64M | 15.16M |
| Cost & Expenses | 151.20M | 102.25M | 89.74M | 49.36M | 26.64M | 15.16M |
| Interest Income | 0.00 | 2.16M | 148.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.59M | 1.92M | 674.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 273.00K | 240.00K | 79.00K | 60.00K | 17.00K | 6.00K |
| EBITDA | -134.46M | -99.85M | -90.19M | -49.50M | -57.19M | -16.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -151.20M | 102.25M | -89.74M | -49.36M | -26.64M | -15.16M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.88M | 242.00K | -526.00K | -203.00K | -30.56M | -986.00K |
| Income Before Tax | -138.32M | -102.01M | -90.27M | -49.56M | -57.20M | -16.15M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.87M | 19.00K | -147.00K | -59.00K | 218.00K | 28.00K |
| Net Income | -142.19M | -102.03M | -90.12M | -49.50M | -57.42M | -16.18M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| EPS Diluted | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| Weighted Avg Shares Out | 71.17M | 34.81M | 20.10M | 16.09M | 10.64M | 4.58M |
| Weighted Avg Shares Out (Dil) | 71.17M | 34.81M | 20.10M | 16.09M | 10.64M | 4.58M |
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
89bio: Bullish In Light Of Further MOA Being Established By Peer
89bio, Inc. has two phase 3 studies underway, known as ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis, which are using pegozafermin to target F2 — F3 and F4 compensated cirrhosis MASH patients respectively. The promise of the two ongoing phase 3 ENLIGHTEN studies is...
89bio Appoints Francis Sarena as Chief Operating Officer
SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena...
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
–The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are enrolling patients–
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, July 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
89bio is a clinical-stage biopharmaceutical company that develops therapies for liver and cardiometabolic conditions. Their drug candidate, pegozafermin, has shown positive results in reducing liver fat and insulin resistance and is in phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH)...
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)—
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
Source: https://incomestatements.info
Category: Stock Reports